Journal of Urologic Oncology

Original Article

July 31, 2026

Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing

Seung-Hwan Jeong, Jang Hee Han, Hyeong Dong Yuk, et al.

J Urol Oncol. 2026;24(2):101-108.

Purpose: This study used the Seoul National University Hospital FIRST-Cancer Panel (v3.2.2) to identify potentially druggable targets in prostate cancer. We compared genetic alterations between primary, treatmentnaive, hormone-sensitive prostate cancer...

Original Article

July 31, 2026

GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure

Ja Yoon Heo, Chung Lee, Heesun Shin, et al.

J Urol Oncol. 2026;24(2):109-118.

Purpose: This study aimed to evaluate the prognostic significance of GATA6 alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel after androgen receptor pathway inhibitor (ARPI) failure. Materials and...

Original Article

July 31, 2026

Expression of Phosphatase-Tensin Homolog and Erythroblast Transformation-Specific Related Genes in Prostate Carcinoma Cases Seen at Osun State University Teaching Hospital, Osogbo, Osun State, Nigeria: A 5-Year Retrospective Observational Study

Olujuwon Towoju, Ganiat Omoniyi-Esan, Akinwumi Komolafe, et al.

J Urol Oncol. 2026;24(2):119-126.

Background: Prostate carcinoma is the second most common cancer in men worldwide and a leading cause of cancer-related mortality, particularly in low- and middle-income countries. Prognostic assessment relies largely on...

Original Article

July 31, 2026

Lesion Volume Dynamics Add Prognostic Value Beyond Prostate Imaging Reporting and Data System Score Increase for Predicting Confirmatory Biopsy Upgrade During Active Surveillance

Theodoros Karanikolas, Jonah Tripp, Morgan Joseph, et al.

J Urol Oncol. 2026;24(2):127-136.

Purpose: This study aimed to evaluate the association of Prostate Imaging Reporting and Data System (PIRADS) score increase and lesion volume progression on serial prostate magnetic resonance imaging (MRI) with...

Brief Report

July 31, 2026

Long-term Follow-up After Prostate-Specific Antigen Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

Eric A. Miller, Paul F. Pinsky

J Urol Oncol. 2026;24(2):137-141.

Current prostate cancer (PCa) screening guidelines for prostate-specific antigen (PSA) testing recommend informed discussions between patient and provider for men aged 55–69 years due to inconsistent trial results and benefit...

Brief Report

July 31, 2026

Prostate-Specific Antigen Surveillance Rates in Sexual Minority Prostate Cancer Survivors During the COVID-19 Pandemic

Ryan Haggart, Alex J. Bates, Badrinath R. Konety, et al.

J Urol Oncol. 2026;24(2):142-146.

While the coronavirus disease 2019 pandemic necessitated delays in nonurgent healthcare, the specific impact on sexual minority cancer patients has remained largely unexamined. In this cross-sectional observational subanalysis of the...

Original Article

July 31, 2026

Integrated Immunophenotypic Stratification of Urothelial Carcinoma Using CK14, FOXA1, and p16: Correlation With Clinicopathological Features and Patient Outcomes

Mona Saeed Mohammed, Nashaat Mohammed Salama

J Urol Oncol. 2026;24(2):147-157.

Purpose: Molecular classification of urothelial carcinoma (UC) has important prognostic and therapeutic implications, but routine genomic profiling is not feasible in many settings. Immunohistochemistry (IHC) offers a practical alternative. This...

Brief Report

July 31, 2026

Specificity of a Urine-Based PENK Methylation Test (EarlyTect Bladder Cancer) in Patients With Benign Urologic Conditions and Healthy Controls

Sang Hun Song, Sangchul Lee

J Urol Oncol. 2026;24(2):158-161.

Bladder cancer (BC) diagnosis relies primarily on cystoscopy and urine cytology. Although cystoscopy is the gold standard, it is invasive and costly, and urine cytology, although noninvasive, has limited sensitivity....

Original Article

July 31, 2026

Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma

Theodore Joseph Miller, Junjia Zhu, Megan Wheelden, et al.

J Urol Oncol. 2026;24(2):162-171.

Purpose: Tyrosine kinase inhibitors (TKIs) used to treat advanced renal cell carcinoma are associated with clinically significant toxicities, including hypertension and acute kidney injury. Because angiotensin-converting enzyme inhibitors and angiotensin...

Review Article

July 31, 2026

Updates on Renal Mass Ablation

Simon Roh, Peter Lee

J Urol Oncol. 2026;24(2):172-181.

Incidental renal masses detected on imaging performed for nonrenal indications are increasingly common in contemporary practice. Appropriate management is essential to achieve favorable patient outcomes while avoiding unnecessary intervention. Percutaneous...

Letter to the Editor

July 31, 2026

A Commentary on “Radical Nephrectomy and Thrombectomy Without Cardiopulmonary Bypass for Level IV Venous Thrombus Renal Cell Carcinoma: Feasibility and Technical Tips”

Matthew Gaynor, Gaetano Ciancio

J Urol Oncol. 2026;24(2):182-183.

Current Issue: Volume 24(2); Jul 2026

Articles in E-pub version are posted online ahead of regular printed publication.

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

MOST READ MOST CITED

11,240	Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma
11,010	Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians
8,436	Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients
7,634	The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
7,210	Prognostic Impact of Seminal Vesicle Mucosal Invasion in pT3b Prostate Cancer Following Radical Prostatectomy

+more

Cited By 11	Health Equity Research Outcomes and Improvement Consortium Prostate Cancer Health Precision Africa1K: Closing the Health Equity Gap Through Rural Community Inclusion
Cited By 8	Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer
Cited By 7	Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
Cited By 5	Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians
Cited By 5	Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review

+more

Editorial Office: Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817, FAX: +82-2-742-4665 Email: journal@e-juo.org

Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: leeseh@yuhs.ac